Risankizumab | Interleukin Related interleukin-related.com

Product Name :
Risankizumab

Search keywords :
Risankizumab

drugId :
null

Target Vo:
Interleukin-23 subunit p19

Target Vo Short Name :
IL-23p19

Moa_Name:
Interleukin-23 subunit p19 inhibitors

First Approval Country :
Japan

First Approval Date Filter:
2019

Origin Company_Name :
C.H. Boehringer Sohn Ag & Co. Kg

Active Company_Name :
Abbvie Deutschland Gmbh & Co Kg

Active Indication_Name:
Psoriasis

In Active Indication_Name:
Spondylitis, Ankylosing

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
NDA/BLA

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Anifrolumab Cancer
TAK1 (Y20P22) Mouse mAb Data Sheet
phospho-PI3 Kinase p110 beta (Ser1070) Antibody: phospho-PI3 Kinase p110 beta (Ser1070) Antibody is an unconjugated, approximately 110-123 kDa, rabbit-derived, anti-phospho-PI3 Kinase p110 beta (Ser1070) polyclonal antibody. phospho-PI3 Kinase p110 beta (Ser1070) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, guinea pig background without labeling.

Author: Interleukin Related

Related Posts